Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01408
|
|||||
| Drug Name |
Ciclesonide
|
|||||
| Synonyms |
Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Asthma [ICD11: CA23] | Approved | [1] | |||
| Therapeutic Class |
Antiallergic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H44O7
|
|||||
| Canonical SMILES |
CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
|
|||||
| InChI |
InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
|
|||||
| InChIKey |
LUKZNWIVRBCLON-GXOBDPJESA-N
|
|||||
| CAS Number |
CAS 141845-82-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 540.7 | Topological Polar Surface Area | 99.1 | ||
| Heavy Atom Count | 39 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
5.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
7848766
, 12014485
, 14763472
, 14910303
, 17194708
, 43529548
, 50069804
, 50113016
, 53790514
, 57371818
, 75476862
, 92719025
, 93307925
, 93815124
, 126592968
, 126621149
, 126652709
, 135211289
, 135805250
, 137002365
, 137619495
, 144206039
, 152134121
, 160668474
, 162183036
, 162258877
, 164788141
, 175266964
, 184545966
, 187051772
, 187072300
, 196106072
, 210279779
, 210282102
, 223657022
, 224423934
, 226395815
, 251915931
, 251917279
, 252215142
, 252347327
|
|||||
| ChEBI ID |
CHEBI:31397
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ciclesonide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.